Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

Published byBernice O’Connor’ Modified over 6 years ago

Similar presentations

Presentation on theme: "Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia."— Presentation transcript:

1 Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol  Gregory A. Yanik, Mary M. Horowitz, Daniel J. Weisdorf, Brent R. Logan, Vincent T. Ho, Robert J. Soiffer, Shelly L. Carter, Juan Wu, John R. Wingard, Nancy L. Difronzo, James L. Ferrara, Sergio Giralt, David K. Madtes, Rebecca Drexler, Eric S. White, Kenneth R. Cooke  Biology of Blood and Marrow Transplantation  Volume 20, Issue 6, Pages (June 2014) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Time to discontinuation of supplemental oxygen support, arm A (etanercept + corticosteroids) versus arm B (placebo + corticosteroids). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Overall survival by treatment arm (months post-randomization). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia."

Similar presentations

How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group.

Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 
Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.
Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia  Vivian.

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia  Vivian.
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications.

Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications.
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.
More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors  Jo-Anne H. Young, MD, Brent R. Logan,

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors  Jo-Anne H. Young, MD, Brent R. Logan,

Similar presentations

Ads by Google